Search Results - "BROWN, Ashley N"

Refine Results
  1. 1

    A sensitive electrochemical immunosensor for label-free detection of Zika-virus protein by Kaushik, Ajeet, Yndart, Adriana, Kumar, Sanjeev, Jayant, Rahul Dev, Vashist, Arti, Brown, Ashley N., Li, Chen-Zhong, Nair, Madhavan

    Published in Scientific reports (26-06-2018)
    “…This work, as a proof of principle, presents a sensitive and selective electrochemical immunosensor for Zika-virus (ZIKV)-protein detection using a…”
    Get full text
    Journal Article
  2. 2

    Nanoparticles Functionalized with Ampicillin Destroy Multiple-Antibiotic-Resistant Isolates of Pseudomonas aeruginosa and Enterobacter aerogenes and Methicillin-Resistant Staphylococcus aureus by BROWN, Ashley N, SMITH, Kathryn, SAMUELS, Tova A, JIANGRUI LU, OBARE, Sherine O, SCOTT, Maria E

    Published in Applied and Environmental Microbiology (01-04-2012)
    “…Classifications Services AEM Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit…”
    Get full text
    Journal Article
  3. 3

    Why Molnupiravir Fails in Hospitalized Patients by Brown, Ashley N, Lang, Yinzhi, Zhou, Jieqiang, Franco, Evelyn J, Hanrahan, Kaley C, Bulitta, Juergen B, Drusano, George L

    Published in mBio (20-12-2022)
    “…Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease 2019 (COVID-19), has radically altered daily life…”
    Get full text
    Journal Article
  4. 4

    Combination Therapy with UV-4B and Molnupiravir Enhances SARS-CoV-2 Suppression by Franco, Evelyn J, Drusano, George L, Hanrahan, Kaley C, Warfield, Kelly L, Brown, Ashley N

    Published in Viruses (16-05-2023)
    “…The host targeting antiviral, UV-4B, and the RNA polymerase inhibitor, molnupiravir, are two orally available, broad-spectrum antivirals that have demonstrated…”
    Get full text
    Journal Article
  5. 5

    Antiviral Activity of the PropylamylatinTM Formula against the Novel Coronavirus SARS-CoV-2 In Vitro Using Direct Injection and Gas Assays in Virus Suspensions by Brown, Ashley N., Strobel, Gary, Hanrahan, Kaley C., Sears, Joe

    Published in Viruses (05-03-2021)
    “…Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of novel coronavirus disease 2019 (COVID-19), has become a severe threat to…”
    Get full text
    Journal Article
  6. 6

    Favipiravir Inhibits Zika Virus (ZIKV) Replication in HeLa Cells by Altering Viral Infectivity by Franco, Evelyn J, Hanrahan, Kaley C, Brown, Ashley N

    Published in Microorganisms (Basel) (22-04-2023)
    “…This study aims to evaluate the antiviral potential of the nucleoside analogue favipiravir (FAV) against ZIKV, an arbovirus for which there are no approved…”
    Get full text
    Journal Article
  7. 7

    Preclinical Evaluations To Identify Optimal Linezolid Regimens for Tuberculosis Therapy by Brown, Ashley N, Drusano, George L, Adams, Jonathan R, Rodriquez, Jaime L, Jambunathan, Kalyani, Baluya, Dodge L, Brown, David L, Kwara, Awewura, Mirsalis, Jon C, Hafner, Richard, Louie, Arnold

    Published in mBio (03-11-2015)
    “…Linezolid is an oxazolidinone with potent activity against Mycobacterium tuberculosis. Linezolid toxicity in patients correlates with the dose and duration of…”
    Get full text
    Journal Article
  8. 8

    Favipiravir Suppresses Zika Virus (ZIKV) through Activity as a Mutagen by Franco, Evelyn J, Cella, Eleonora, Tao, Xun, Hanrahan, Kaley C, Azarian, Taj, Brown, Ashley N

    Published in Microorganisms (Basel) (19-05-2023)
    “…In a companion paper, we demonstrated that the nucleoside analogue favipiravir (FAV) suppressed Zika virus (ZIKV) replication in three human-derived cell…”
    Get full text
    Journal Article
  9. 9

    UV-4B potently inhibits replication of multiple SARS-CoV-2 strains in clinically relevant human cell lines by Franco, Evelyn J, Warfield, Kelly L, Brown, Ashley N

    Published in Frontiers in bioscience (Landmark. Print) (05-01-2022)
    “…SARS-CoV-2 is the coronavirus responsible for the COVID-19 pandemic. Although it poses a substantial public health threat, antiviral regimens against…”
    Get full text
    Journal Article
  10. 10

    Antiviral Evaluation of UV-4B and Interferon-Alpha Combination Regimens against Dengue Virus by Franco, Evelyn J, Pires de Mello, Camilly P, Brown, Ashley N

    Published in Viruses (27-04-2021)
    “…Dengue virus (DENV) is a flavivirus associated with clinical manifestations ranging in severity from self-limiting dengue fever, to the potentially life…”
    Get full text
    Journal Article
  11. 11

    Nebivolol Improves Diastolic Dysfunction and Myocardial Remodeling Through Reductions in Oxidative Stress in the Zucker Obese Rat by Zhou, Xinli, Ma, Lixin, Habibi, Javad, Whaley-Connell, Adam, Hayden, Melvin R, Tilmon, Roger D, Brown, Ashley N, Kim, Jeong-a, DeMarco, Vincent G, Sowers, James R

    Published in Hypertension (Dallas, Tex. 1979) (01-04-2010)
    “…Insulin resistance is associated with obesity and may be accompanied by left ventricular diastolic dysfunction and myocardial remodeling. Decreased insulin…”
    Get full text
    Journal Article
  12. 12

    Persistence of West Nile virus in the central nervous system and periphery of mice by Appler, Kim K, Brown, Ashley N, Stewart, Barbara S, Behr, Melissa J, Demarest, Valerie L, Wong, Susan J, Bernard, Kristen A

    Published in PloS one (14-05-2010)
    “…Most acute infections with RNA viruses are transient and subsequently cleared from the host. Recent evidence, however, suggests that the RNA virus, West Nile…”
    Get full text
    Journal Article
  13. 13

    Antiviral Effects of Clinically-Relevant Interferon-α and Ribavirin Regimens against Dengue Virus in the Hollow Fiber Infection Model (HFIM) by Pires de Mello, Camilly P, Drusano, George L, Rodriquez, Jaime L, Kaushik, Ajeet, Brown, Ashley N

    Published in Viruses (09-06-2018)
    “…Dengue virus (DENV) is the most prevalent mosquito-borne viral illness in humans. Currently, there are no therapeutic agents available to prevent or treat DENV…”
    Get full text
    Journal Article
  14. 14

    Modeling the viral dynamics of SARS-CoV-2 infection by Wang, Sunpeng, Pan, Yang, Wang, Quanyi, Miao, Hongyu, Brown, Ashley N., Rong, Libin

    Published in Mathematical biosciences (01-10-2020)
    “…Coronavirus disease 2019 (COVID-19), an infectious disease caused by the infection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is…”
    Get full text
    Journal Article
  15. 15

    Sofosbuvir (SOF) Suppresses Ledipasvir (LDV)-resistant Mutants during SOF/LDV Combination Therapy against Genotype 1b Hepatitis C Virus (HCV) by Brown, Ashley N., Liu, Lin, Rodriquez, Jaime L., Zhao, Lisa, Schuster, Layla, Li, Eric, Wang, Gary P., Neely, Michael N., Yamada, Walter, Drusano, George L.

    Published in Scientific reports (31-10-2017)
    “…Our objective was to identify drug interactions between ledipasvir (LDV) and sofosbuvir (SOF) against a genotype 1b replicon to determine optimal exposures for…”
    Get full text
    Journal Article
  16. 16

    Utility of a Novel Three-Dimensional and Dynamic (3DD) Cell Culture System for PK/PD Studies: Evaluation of a Triple Combination Therapy at Overcoming Anti-HER2 Treatment Resistance in Breast Cancer by Ande, Anusha, Vaidya, Tanaya R, Tran, Bao N, Vicchiarelli, Michael, Brown, Ashley N, Ait-Oudhia, Sihem

    Published in Frontiers in pharmacology (01-05-2018)
    “…Emergence of Human epidermal growth factor receptor 2 (HER2) therapy resistance in HER2-positive (HER2+) breast cancer (BC) poses a major clinical challenge…”
    Get full text
    Journal Article
  17. 17

    Combination Regimens of Favipiravir Plus Interferon Alpha Inhibit Chikungunya Virus Replication in Clinically Relevant Human Cell Lines by Franco, Evelyn J, Tao, Xun, Hanrahan, Kaley C, Zhou, Jieqiang, Bulitta, Jürgen B, Brown, Ashley N

    Published in Microorganisms (Basel) (02-02-2021)
    “…Chikungunya virus (CHIKV) is an alphavirus associated with a broad tissue tropism for which no antivirals or vaccines are approved. This study evaluated the…”
    Get full text
    Journal Article
  18. 18

    Zanamivir, at 600 Milligrams Twice Daily, Inhibits Oseltamivir-Resistant 2009 Pandemic H1N1 Influenza Virus in an In Vitro Hollow-Fiber Infection Model System by BROWN, Ashley N, MCSHARRY, James J, QINGMEI WENG, ADAMS, Jonathan R, KULAWY, Robert, DRUSANO, George L

    Published in Antimicrobial Agents and Chemotherapy (01-04-2011)
    “…Classifications Services AAC Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit…”
    Get full text
    Journal Article
  19. 19

    Effect of Half-Life on the Pharmacodynamic Index of Zanamivir against Influenza Virus Delineated by a Mathematical Model by Brown, Ashley N, Bulitta, Jürgen B, McSharry, James J, Weng, Qingmei, Adams, Jonathan R, Kulawy, Robert, Drusano, George L

    Published in Antimicrobial Agents and Chemotherapy (01-04-2011)
    “…Classifications Services AAC Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit…”
    Get full text
    Journal Article
  20. 20

    In Vitro System for Modeling Influenza A Virus Resistance under Drug Pressure by BROWN, Ashley N, MCSHARRY, James J, QINGMEI WENG, DRIEBE, Elizabeth M, ENGELTHALER, David M, SHEFF, Kelly, KEIM, Paul S, NGUYEN, Jack, DRUSANO, George L

    Published in Antimicrobial Agents and Chemotherapy (01-08-2010)
    “…Classifications Services AAC Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit…”
    Get full text
    Journal Article